-
Uncategorized4 weeks agoInfinitopes appoints CSO to advance immuno-oncology pipeline
Biotechnology company Infinitopes has appointed Jo Brewer as Chief Scientific Officer (CSO) and interim Chief Operating Officer (COO). The company hopes Brewer’s appointment will allow it to advance...
-
Uncategorized4 weeks agoCreate Medicines raises $122M to bolster in vivo CAR-T therapies
The fresh funds will support the biotech’s pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
-
Uncategorized4 weeks ago
Drugmakers have to go through rigorous tests to get a lower tariff rate
Landing a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald...
-
Uncategorized4 weeks ago
Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data
Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data
-
Uncategorized4 weeks ago
REGENXBIO slumps after serious side effects mar Duchenne gene therapy results
Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company’s first quarter earnings call Thursday.
-
Uncategorized4 weeks agoSTAT+: BeOne wins FDA approval in lymphoma race
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boom keeps...
-
Uncategorized4 weeks ago
Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism
While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted biomarker and cognitive improvements from the Phase 2 study, leaving analysts...
-
Uncategorized4 weeks ago
How Penn Medicine plans to use AI to train their doctors
Physicians at Penn Medicine said they’re thinking of how to use AI to train doctors. The idea came out of a $1.1 million grant Penn Medicine...
-
Uncategorized4 weeks ago
Biotech leaders pitch Pazdur as next FDA chief
In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to lead the agency after the departure of...
-
Uncategorized4 weeks ago
Degron adds $40M to series A, supporting immunology plans for molecular glue platform
Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa Therapeutics last year to develop molecular glues for...
SonoThera Raises $125M to Develop Ultrasound-Mediated Genetic Medicines
